Colin Edgerton, MD
Rheumatology · Summerville, SCNPI 1245307578
Payments from drug & device makers
What this record shows
This record is dominated by other: $2,300,000 of the $3,501,795 with a category attached, or 65.7%. American Rheumatology Network, LLC accounts for 97.9% of it on its own, with 31 other manufacturers making up the rest. Among rheumatology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 804 payments — averaging $4355.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- American Rheumatology Network, LLC$3.4M
- AbbVie$22K
- Pfizer$11K
- Amgen$7K
- Novartis$7K
- Sobi, Inc$6K
- plus $20K from 26 others
Across 45 payments — averaging $6388.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$171K
- Amgen$49K
- AbbVie$27K
- Dr.reddy's Laboratories,inc.$25K
- AstraZeneca$10K
- Ironwood Pharmaceuticals, Inc$4K
- plus $776 from 1 others
Across 6 payments — averaging $133,333 each. An ownership or investment interest held by the physician or an immediate family member.
- American Rheumatology Network, LLC$800K
What the payments were for
- Consulting fees$399,65111%
- Speaking & faculty fees$15,2650%
- Grants$16,2500%
- Travel & lodging$4,4580%
- Food & beverage$16,8810%
- Education$6780%
- Ownership interest$748,61121%
- Other$2,300,00066%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| American Rheumatology Network, LLC | 18 | $3,428,746 |
| AbbVie | 117 | $21,793 |
| Pfizer | 26 | $10,741 |
| Amgen(2 entities) | 149 | $7,405 |
| Novartis | 63 | $7,071 |
| Sobi, Inc | 14 | $6,382 |
| Boehringer Ingelheim | 22 | $5,432 |
| Johnson & Johnson | 114 | $4,173 |
| UCB, Inc. | 61 | $3,628 |
| Sandoz | 5 | $1,591 |
| AstraZeneca(2 entities) | 39 | $1,171 |
| E.r. Squibb & Sons, L.L.C. | 54 | $721 |
| GSK | 39 | $653 |
| Organon | 15 | $411 |
| Lilly USA, LLC | 19 | $347 |
| Mckesson Specialty Care Distribution, LLC | 4 | $277 |
| Octapharma USA, Inc. | 1 | $273 |
| Aurinia Pharma U.S., Inc. | 10 | $247 |
| Genentech USA, Inc. | 8 | $160 |
| Biogen | 1 | $103 |
| Sanofi | 5 | $102 |
| Fresenius Kabi USA, LLC | 4 | $95 |
| ANI Pharmaceuticals, Inc. | 3 | $58 |
| Hikma Pharmaceuticals USA | 3 | $48 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Merck | 2 | $24 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Radius Health, Inc. | 1 | $22 |
| Almatica Pharma LLC | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $15 |
| Medexus Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,501,795 in reported general payments places this provider in the 95th percentile of 123 rheumatology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 33 | $413,574 |
| TavneosAvacopan | 11 | $184,915 |
| RinvoqUpadacitinib | 13 | $111,854 |
| Cimzia (2 Pack)Certolizumab Pegol | 12 | $91,680 |
| Hydroxychloroquine Sulfate | 140 | $8,186 |
| Duloxetine Hcl | 98 | $3,355 |
| Cevimeline Hcl | 25 | $3,301 |
| MethotrexateMethotrexate Sodium | 102 | $2,731 |
| Celecoxib | 51 | $2,544 |
| Mycophenolate Mofetil | 12 | $2,203 |
| Prednisone | 324 | $2,146 |
| Pregabalin | 42 | $2,052 |
| Gabapentin | 68 | $1,618 |
| Leflunomide | 16 | $1,240 |
| Colchicine | 16 | $1,051 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenTavneos | $7,405 | $184,91511 claims |
| AbbVieRinvoq | $21,793 | $111,85413 claims |
| UCB, Inc.Cimzia (2 Pack) | $3,628 | $91,68012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 123 rheumatology providers in South Carolina.
Other rheumatology in Summerville
- Gregory NiemerSummerville$2.9M
- Gary FinkSummerville$2.9M
- Clarence LegertonSummerville$2.9M
- Jennifer MurphySummerville$2.8M
- William EdwardsSummerville$1.3M
- Nicholas HoldgateSummerville$23K
- Bradley CollinsSummerville$6K
- Durga AdhikariSummerville$5K
- Alan BrownGreenville$947K
- Douglas ConawayMyrtle Beach$500K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.